Page 28 - Pharma Bio News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Nicox Provides Fourth Quarter 2020 Business Update and Financial Highlights Nicox Provides Fourth Quarter 2020 Business Update and Financial Highlights Initiated two large clinical trials: Denali, the second Phase 3 of NCX 470 in glaucoma, and Mississippi, a Phase 2b of NCX 4251 in blepharitis Phase 3 clinical trial of ZERVIATE in allergic conjunctivitis initiated by partner Ocumension Therapeutics in China U.S. prescriptions for VYZULTA TM by 56% over Q3 2020 Q4 2020 net revenue of €5.8 million, full year 2020 net revenue of €8.9 million and cash of €47.8 million at December 31, 2020 ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ERYTECH to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference Erytech Pharma S.A.January 6, 2021 GMT ERYTECH to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference Lyon (France) and Cambridge, MA (U.S.), January 6, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced today that CEO, Gil Beyen, will present at the H.C....

Nicox's Partner Ocumension Therapeutics Initiates ZERVIATE Phase 3 Clinical Trial in China December 30, 2020 - release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that its partner, Ocumension Therapeutics, has initiated a Phase 3 clinical trial in China with ZERVIATE TM, the first and only topical ocular formulation of the antihistamine cetirizine, for the treatment of ocular itching associated with allergic conjunctivitis. Gavin Spencer, Chief Business Officer at Nicox, said: " Our teams work...

ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer A total of 510 patients enrolled Events required to trigger interim superiority analysis accrued Interim superiority analysis expected in Q1 2021; final analysis in Q4 2021 LYON, France and CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the completion of enrollment in the TRYbeCA-1 Phase 3 trial in ...

The event will be held virtually, with all corporate and institutional participants joining remotely. A webcast of the event will be available by clicking here and will be accessible via ERYTECH's website at http://www.erytech.com/investors/webcast/ About ERYTECH and eryaspase ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipelin...